Healthcare · Pharmaceuticals & Biotechnology
QVM read Quality at a discount Quality Strong, Valuation Undervalued, Momentum Neutral
Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.
Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations, active pharmaceutical ingredients and agrochemical products. It is a major producer of branded oncology medicines cardiology, diabetology and other pharma specialty drugs at affordable prices.
Source: Wikipedia
Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.
PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.
Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.
Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.
Ranks #38 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.
| Filed | Person | Category | Type | Quantity | Value |
|---|---|---|---|---|---|
| 11 Mar 2026 | SATYA VANI NANNAPANENI | Promoter group | Sell | 0 | ₹0 |
| 11 Mar 2026 | SANJAY NANNAPANENI | Promoter group | Sell | 0 | ₹0 |
| 1 Oct 2025 | SANJAY NANNAPANENI | Promoter group | Sell | 0 | ₹0 |
| 17 Sep 2025 | SATYA VANI NANNAPANENI | Promoter group | Sell | 0 | ₹0 |
| 11 Sep 2025 | SATYA VANI NANNAPANENI | Promoter group | Sell | 0 | ₹0 |
| 12 Jun 2025 | PRAGNYA RAO DONTHINENI | Other | Buy | 0 | ₹0 |
| 27 Mar 2025 | SANJAY NANNAPANENI | Promoter group | Buy | 0 | ₹0 |
| 21 Mar 2025 | VENKATA SATYA SWATHI KANTAMANI | Promoter group | Sell | 0 | ₹0 |
| 21 Mar 2025 | RAJEEV NANNAPANENI | Promoter | Sell | 0 | ₹0 |
| 3 Mar 2025 | SANJAY NANNAPANENI | Promoter group | Buy | 0 | ₹0 |
| Date | Client | Deal | Action | Quantity | Price | Exchange |
|---|---|---|---|---|---|---|
| 24 Apr 2025 | GRAVITON RESEARCH CAPITAL LLP | Bulk | Buy | 1,784,917 | 929.7100 | NSE |
| 24 Apr 2025 | GRAVITON RESEARCH CAPITAL LLP | Bulk | Sell | 1,784,917 | 930.1900 | NSE |
| 14 Feb 2025 | GRAVITON RESEARCH CAPITAL LLP | Bulk | Sell | 971,727 | 891.0300 | NSE |
| 14 Feb 2025 | GRAVITON RESEARCH CAPITAL LLP | Bulk | Buy | 971,727 | 890.8600 | NSE |
| 21 Feb 2024 | JUPITER SOUTH ASIA INVESTMENT COMPANY LIMITED | Block | Sell | 198,742 | 1039.1500 | BSE |
| 21 Feb 2024 | THE JUPITER GLOBAL FUND-JUPITER INDIA SELECT | Block | Buy | 198,742 | 1039.1500 | BSE |
| 25 Jan 2024 | MARSHALLWACEINVESTMENTSTRATEGIESMARKETNEUTRALTOPSFUND | Block | Buy | 149,926 | 859.2000 | BSE |
| 25 Jan 2024 | BNP PARIBAS ARBITRAGE | Block | Sell | 149,926 | 859.2000 | BSE |
| 25 Jan 2024 | SOCIETE GENERALE | Block | Buy | 662,733 | 859.2000 | BSE |
| 25 Oct 2022 | ISHARES INDIA SC MAURITIUS COMPANY | Block | Sell | 22,874 | 593.9000 | BSE |
| Ex-date | Subject | Per share (₹) | Record date |
|---|---|---|---|
| — | Interim Dividend - Rs. - 1.5000 | — | — |
Quarterly results, AGMs, buybacks and other board-approved business.
| Date | Purpose | Results |
|---|---|---|
| 25 Sep 2026 | Fund Raising | — |
| 14 Aug 2026 | Fund Raising | — |
| 14 Aug 2026 | Financial Results/Dividend | Yes |
| 29 May 2026 | Financial Results | Yes |
| 24 Mar 2026 | Other business matters | — |
Exchange disclosures (NSE and BSE), most recent first.
| Date | Category | Announcement |
|---|---|---|
| 30 Sep 2026 | AGM/EGM | Natco Pharma Ltd - 524816 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report |
| 30 Sep 2026 | AGM/EGM | Natco Pharma Ltd - 524816 - Shareholder Meeting / Postal Ballot-Outcome of AGM |
| 30 Sep 2026 | Insider Trading / SAST | Natco Pharma Ltd - 524816 - Closure of Trading Window |
| 28 Sep 2026 | Others | Natco Pharma Ltd - 524816 - Board Meeting Outcome for Outcome Of Fund Raising Committee Meeting Approving The Letter Of Offer For Rights Issue |
| 28 Sep 2026 | Company Update | Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release |
| 25 Sep 2026 | Board Meeting | Natco Pharma Ltd - 524816 - Board Meeting Outcome for Out Come Of Board Meeting |
| 25 Sep 2026 | Company Update | Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Issue of Securities |
| 25 Sep 2026 | Corp. Action | Natco Pharma Ltd - 524816 - Intimation Of Record Date For Rights Issue |
| 21 Sep 2026 | Company Update | Natco Pharma Ltd - 524816 - Receipt Of In-Principal Approval For Rights Issue Of Equity Shares |
| 9 Sep 2026 | Board Meeting | Natco Pharma Ltd - 524816 - Board Meeting Outcome for Outcome Of Board Meeting |
Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.
Data unavailable.
Data unavailable.
Board of directors and corporate information →
Data unavailable (no single-stock futures or options activity on record for this company).
The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.
The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.
The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.
No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.
